Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

The Efficacy and Safety of Polyethylene Glycol Cholesterol- and Tocopherol Polyethylene Glycol 1000 Succinate-Modified Transforming Growth Factor β1 Small Interfering RNA Lipid Nanoparticles in the Treatment of Paclitaxel-Resistant Non-Small-Cell Lung Cancer

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

PTD Modified Paclitaxel Anti-Resistant Liposomes for Treatment of Drug-Resistant Non-Small Cell Lung Cancer

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

A Novel Paclitaxel-Loaded Poly(d,l-Lactide-co-glycolide)-tween 80 Copolymer Nanoparticle Overcoming Multidrug Resistance for Lung Cancer Treatment

Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

Co-delivery of Paclitaxel and Anti-Vegf Sirna by Tripeptide Lipid Nanoparticle to Enhance the Anti-Tumor Activity for Lung Cancer Therapy.

Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration

Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate Non-Small-cell Lung Cancers in Vivo

PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Improving Drug Delivery of Micellar Paclitaxel against Non-Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator.

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugate in Resistant Lung Cancer

Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.

Assessing the Clinical Outcome of Nab-Paclitaxel in Chinese Patients with Advanced Non-Small-cell Lung Cancer.

The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma

Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer

Overcoming Drug-Resistant Lung Cancer by Paclitaxel Loaded Tetrahedral DNA Nanostructures.